OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING
Oroxylin A is a potential inhibitory compound that could be applied to treat rheumatoid arthritis (RA). Rheumatoid arthritis is a chronic, systemic autoimmune disease that can lead to joint damage, deformity, and disability if not effectively treated. Current research utilizes network pharmacol...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Trường Đại học Vinh
2025-03-01
|
| Series: | Tạp chí Khoa học |
| Subjects: | |
| Online Access: | https://vujs.vn//api/view.aspx?cid=0793f0df-a326-4dc4-9c03-6cbdc25fcea9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Oroxylin A is a potential inhibitory compound that could be
applied to treat rheumatoid arthritis (RA). Rheumatoid
arthritis is a chronic, systemic autoimmune disease that can
lead to joint damage, deformity, and disability if not
effectively treated. Current research utilizes network
pharmacology and molecular docking methods to predict the
primary mechanism of action of oroxylin A against
rheumatoid arthritis. Through screening via protein-protein
interaction networks (PPI), 67 potential RA-related targets
have been identified, with EGFR, PTGS2, ESR1, MMP9, and
GSK3B potentially serving as central targets. KEGG pathway
analysis indicates that these 67 potential targets are associated
with pathways related to metabolism, pathways in cancer,
PI3K-Akt signalling pathway, Ras signalling pathway, and
microRNAs in cancer. Molecular docking has been applied to
determine the binding mode and affinity of oroxylin A with
these five central RA-related targets. These findings offer the
potential to inhibit relevant biological targets and provide a
basis for further research into the mechanism of oroxylin A
against RA. |
|---|---|
| ISSN: | 1859-2228 |